Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT-MS
2016-003587-39Phase 4Completed
- Sponsor
- Karolinska Institutet
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab, natalizumab, dimethyl fumarate, fingolimod, glatiramer acetate and 4 more in multiple sclerosis (MS) (9 arms), sponsored by Karolinska Institutet. Primary endpoint: Co-primary endpoints. Started Mar 2017; status: completed.
02
Drugs
rituximabnatalizumabdimethyl fumaratefingolimodglatiramer acetate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2016-003587-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003587-39.